Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vericel Corp Director's Dealing 2026

Feb 20, 2026

31799_dirs_2026-02-20_704d1291-6836-4dba-9c7f-4c8590b35ffb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vericel Corp (VCEL)
CIK: 0000887359
Period of Report: 2026-02-18

Reporting Person: Colangelo Dominick (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2026-02-18 Common Stock M 18250 Acquired 278727 Direct
2026-02-18 Common Stock M 11700 Acquired 290427 Direct
2026-02-18 Common Stock F 5657 $37.41 Disposed 284770 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2026-02-18 Restricted Stock Unit $ M 18250 Acquired Common Stock (18250) Direct
2026-02-18 Restricted Stock Unit $ M 11700 Acquired Common Stock (11700) Direct
2026-02-19 Stock Option (Right to Buy) $38.17 A 182500 Acquired 2036-02-19 Common Stock (182500) Direct
2026-02-19 Restricted Stock Unit $ A 73000 Acquired Common Stock (73000) Direct

Footnotes

F1: The Restricted Stock Units (RSUs) converted to phantom stock units and are deferred under the Vericel Corporation Deferred Compensation Plan. The units will be payable only in shares of Common Stock upon the Reporting Person's elected Benefit Distribution Date.

F2: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 17, 2023. The remaining RSUs will vest on February 17, 2027. Upon the vesting of RSUs granted to the Reporting Person on February 17, 2023, the Reporting Person deferred the receipt of 18,250 shares of Common Stock and instead received 18,250 shares of Phantom Stock pursuant to the Vericel Corporation Deferred Compensation Plan.

F3: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F4: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 18, 2022.

F5: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.

F6: Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.

F7: No expiration date for this type of award.

F8: The Fair Market Value of the vested derivative securities is $37.41 per share.

F9: These options shall begin vesting on February 19, 2026 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.

F10: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2027. The remaining RSUs will vest in annual installments on February 19, 2028, February 19, 2029, and February 19, 2030, respectively.